Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA-2
NCT07743450Phase 3Recruiting
- Sponsor
- Ascletis Pharma Inc.
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 6
01
Overview
A Phase 3 trial of ASC30 in obesity, type 2 diabetes mellitus (T2DM), sponsored by Ascletis Pharma Inc.. Started Aug 2026; status: recruiting.
02
Drugs
ASC30
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07743450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743450.